89 related articles for article (PubMed ID: 18314623)
1. [Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma].
Kern MA; Schirmacher P; Breinig M
Verh Dtsch Ges Pathol; 2007; 91():257-68. PubMed ID: 18314623
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M
Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma.
Kern MA; Haugg AM; Eiteneuer E; Konze E; Drebber U; Dienes HP; Breuhahn K; Schirmacher P; Kasper HU
Liver Int; 2006 Jun; 26(5):604-12. PubMed ID: 16762006
[TBL] [Abstract][Full Text] [Related]
4. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X
J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice.
Kern MA; Schöneweiss MM; Sahi D; Bahlo M; Haugg AM; Kasper HU; Dienes HP; Käferstein H; Breuhahn K; Schirmacher P
Carcinogenesis; 2004 Jul; 25(7):1193-9. PubMed ID: 14963015
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 (COX-2)--a therapeutic target in liver cancer?
Breinig M; Schirmacher P; Kern MA
Curr Pharm Des; 2007; 13(32):3305-15. PubMed ID: 18045183
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Bae SH; Jung ES; Park YM; Kim BS; Kim BK; Kim DG; Ryu WS
Clin Cancer Res; 2001 May; 7(5):1410-8. PubMed ID: 11350912
[TBL] [Abstract][Full Text] [Related]
8. Regression of hepatocellular carcinoma due to cyclooxygenase (COX)-2 inhibitor.
Dohmen K; Okabe H; Ishibashi H
Am J Gastroenterol; 2006 Oct; 101(10):2437-8. PubMed ID: 17032211
[No Abstract] [Full Text] [Related]
9. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
10. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 in hepatocellular carcinoma.
Wu T
Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
15. COX-2 expression and effects of COX-2 inhibition in colorectal carcinomas and their liver metastases.
Kasper HU; Konze E; Dienes HP; Stippel DL; Schirmacher P; Kern M
Anticancer Res; 2010 Jun; 30(6):2017-23. PubMed ID: 20651346
[TBL] [Abstract][Full Text] [Related]
16. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
Chen Y; Chen HN; Wang K; Zhang L; Huang Z; Liu J; Zhang Z; Luo M; Lei Y; Peng Y; Zhou ZG; Wei Y; Huang C
J Hepatol; 2019 Jan; 70(1):66-77. PubMed ID: 30287340
[TBL] [Abstract][Full Text] [Related]
17. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
[TBL] [Abstract][Full Text] [Related]
19. The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma.
Chi-Man Tang T; Tung-Ping Poon R; Fan ST
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S311-6. PubMed ID: 16507400
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenases in hepatocellular carcinoma.
Cervello M; Montalto G
World J Gastroenterol; 2006 Aug; 12(32):5113-21. PubMed ID: 16937518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
